BioSpace News Archive

Idorsia Pharmaceuticals, U.S. Inc., announced that results from the Wake Up America survey, conducted by The Alliance for Sleep and sponsored by Idorsia, will be presented at SLEEP 2022, the 36th annual congress hosted by the Associated Professional Sleep Societies.

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a preclinical study in blood entitled “ A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and Hematological Malignancies ”.

Thermo Fisher Scientific Inc., the world leader in serving science, is providing proteomics and biopharmaceutical laboratories working in drug discovery and R&D applications with an innovative mass spectrometry solution that, for the first time, unlocks the ability to clearly decipher complex mixtures of large macromolecules.

Thermo Fisher Scientific Inc., the world leader in serving science, is providing forensic toxicologists, clinical research toxicologists, employee drug testing facilities, and wellness organizations with an all-in-one liquid chromatography-mass spectrometry toxicology solution to keep pace with the ever-changing landscape of emerging and illicit drugs.

Thermo Fisher Scientific Inc., the world leader in serving science, is helping proteomics researchers increase productivity and free up time for more value-added activities when generating high quality samples for analysis, using a new automated sample preparation system that integrates within any LC-MS workflow.

Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system.

AltruBio Inc. announced that president and chief executive officer Judy Chou, Ph.D., will present an in-person corporate overview at the 2022 BIO International Convention taking place June 13-16, 2022 in San Diego, Calif.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor ABI-H3733 (3733).

Corcept Therapeutics Incorporated announced that, following consultation with the U.S. Food and Drug Administration, it will start a registrational Phase 3 trial of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), today announced that the company will participate in the newly formed Metropolitan AntiViral Drug Accelerator (MAVDA) which was recently awarded a three-year, $65,141,731 grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Disease (NIAID)’s Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program.